10 research outputs found
Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium - Fig 4
<p>ROC-curves of the cGMP/Creatinine ratio before CM application for (a) death, (b) dialysis and (c) MARE.</p
Multivariate logistic regression analysis for predictors of MARE.
<p>Multivariate logistic regression analysis for predictors of MARE.</p
Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium - Fig 3
<p><b>Distribution of urinary cGMP/creatinine ratios (μM/mM) before 24 hours after and 48h after contrast media application detected in patients without (No) or with (Yes) following adverse events: death(a), dialysis (b) or MARE (c).</b><i>cGMP</i>: <i>urinary cyclic guanosine monophosphate</i>, <i>MARE</i>: <i>major adverse renal event</i>, <i>*** p<0</i>.<i>001</i>, <i>** p<0</i>.<i>01</i>, <i>* p<0</i>.<i>05</i>.</p
Sensitivity analysis.
<p>The sensitivity analysis recalculates the net expected cost of each strategy (Scr vs. uNGAL+Scr), varying one model input at a time to its high and low values relative to its baseline value. At both sites, costs of uNGAL+Scr remain lower for each scenario examined in the sensitivity analysis. At NYP-Allen and SIUH, the results are most sensitive to hospital costs and length of stay, costs of additional testing, and the percent of patients with CKD.</p
Effects on cost per patient.
<p>Effects on Cost Per Patient at NYP-Allen and SIUH. At NYP-Allen, the use of uNGAL+Scr would lead to an expected cost savings of 522 per patient at SIUH. These savings were reflected in lower per patient hospitalization costs and lower additional testing costs.</p
Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium - Fig 2
<p><b>Histogram of cGMP/Creatinine ratio (μM/mM) (a) before, (b) 24h after and (c) 48h after CM application.</b><i>cGMP</i>: <i>urinary cyclic guanosine monophosphate</i>.</p
Simulation model.
<p>A cost simulation model was developed for competing testing strategies to evaluate for AKI; 1) Scr alone, vs. 2) uNGAL plus Scr (uNGAL+Scr). Since the uNGAL+Scr treatment arm provided more diagnostic information, it was regarded as the “gold standard” relative to Scr alone in terms of whether patients should be treated or whether treatment should be delayed.</p